Glutathione-mediated release of Bodipy® from PEG cofunctionalized gold nanoparticles

Dhiraj Kumar
Brian J Meenan
Dorian Dixon
Nanotechnology and Integrated BioEngineering Centre, University of Ulster, Belfast, Northern Ireland

Abstract: Gold nanoparticles synthesized via sodium citrate reduction of chloroauric acid (HAuCl₄) were functionalized with either various concentrations of thiol-terminated Bodipy® FL L-cystine (0.5, 1.0, 1.5, and 2.0 µg/mL) or Bodipy-poly(ethylene glycol) at concentrations of 0.5–18.75, 1.0–12.50, and 1.5–6.25 µg/mL to form a mixed monolayer of BODIPY-PEG. Thiol-terminated Bodipy, a fluorescing molecule, was used as the model drug, while PEG is widely used in drug-delivery applications to shield nanoparticles from unwanted immune responses. Understanding the influence of PEG-capping on payload release is critical because it is the most widely used type of nanoparticle functionalization in drug delivery studies. It has been previously reported that glutathione can trigger release of thiol-bound payloads from gold nanoparticles. Bodipy release from Bodipy capped and from Bodipy-PEG functionalized gold nanoparticles was studied at typical intracellular glutathione levels. It was observed that the addition of PEG capping inhibits the initial burst release observed in gold nanoparticles functionalized only with Bodipy and inhibits nanoparticle aggregation. Efficient and controlled payload release was observed in gold nanoparticles cofunctionalized with only a limited amount of PEG, thus enabling the coattachment of large amounts of drug, targeting groups or other payloads.

Keywords: gold nanoparticles, FL L-cystine, Bodipy®, poly(ethylene glycol), glutathione-mediated release, photoluminescence

Introduction

Gold nanoparticles have shown great potential application in the biomedical fields of immunostaining,¹,² phagokinetics,³ in single particle tracking,⁴ as contrast agents,⁵ and in drug delivery.⁶ Gold nanoparticles can be readily synthesized in sizes of 1–150 nm from gold salt solutions, using reducing agents such as sodium citrate or sodium borohydride. It has been reported that both the payload delivery and toxicity of nanoparticles depend to a significant degree on particle size.⁷ Gold nanoparticles can be easily functionalized with a wide range of drugs, targeting and shielding groups using thiol linkers.⁸ Due to the noncovalent interaction of DNA with gold nanoparticles, DNA-gold complexes have been also been used in gene delivery,⁹ biosensing, diagnostics, finding complementary DNA sequences, and in nanocrystal formation.⁸ Numerous studies have found that gold nanoparticles can be internalized in cells; and with appropriate surface modification using membrane-bound transferrin ligands, specific cellular uptake is possible.¹⁰,¹¹ For example, gold nanoparticles which are surface modified with folate receptors have been used for targeting cancer cells,¹² and with the presence of peptides on the surface, direct translocation to the nucleus has been observed.¹³
As noted, the surface of gold nanoparticles can be readily cofunctionalized with a wide range of groups for different functions. The stability of metallic nanoparticles in a range of media and their circulation time in vivo can be increased using capping agents such as polyethylene glycol (PEG), mercaptosuccinic acid, mercaptopropionic acid, and various block polymers, leading to improved stability at various pH levels and at physiological salt concentrations. These antifouling coatings can be combined with other groups, such as drug payloads and targeting agents. For example, Shenoy functionalized gold nanoparticles with coumarin as a fluorescent dye using PEG as a spacer, while modification with a mixed PEG-peptide conjugate has been used to target the cytoplasm of HeLa cells. Meanwhile, Dreaden et al used gold nanoparticles capped with both PEG and tamoxifen to target and deliver the drug to breast cancer cells using the estrogen receptor. In another study, PEG-functionalized gold nanoparticles were conjugated with monoclonal F19 antibodies to target human pancreatic carcinoma tissues.

The formulation CYT-6091 which is tumor necrosis factor and PEG on gold nanoparticles, has been tested for the treatment of tumors in a mouse model. It was reported that these gold nanoparticles accumulated in tumors, resulting in reduced tumor size and an increased mean survival time, and this work is now proceeding to clinical trials in humans. The studies have shown that PEGylated nanoparticles can overcome rapid removal by the reticuloendothelial system, and after payload release, the nanoparticles were extracted from the systemic circulation by cells in the liver.

Release of the payload at the required site can be achieved using photoexcitation or by means of intracellular glutathione levels. The intracellular concentration of glutathione is 1–10 mM, whereas extracellular levels are 2 μM, which can be used to break the thiol linker, releasing the payload inside the cell. For example, an eight-fold increase in the release of Bodipy fluorescence from gold nanoparticles cofunctionalized with tetra (ethylene glycol)-lyated cationic ligand was observed in the presence of typical intracellular levels of glutathione.

While the influence of PEG on the stability, circulation time, and biological fate of gold nanoparticles has been widely studied, the effect of such cofunctionalization on payload release is not fully understood. The presence of large PEG molecules on the surface of gold nanoparticles will likely influence any interactions with other groups on the surface through steric effects, altering payload release. In this study, we use the quenching properties of gold nanoparticles to study the release of a thiol-terminated fluorescent dye (Bodipy) from gold nanoparticles with and without PEG capping in glutathione over a period of 5 days using photoluminescence spectroscopy. Such data would be of interest in the development of mixed monolayer surface coatings for gold nanoparticle drug-delivery systems.

Materials and methods

Materials

Chloroaucic acid (HAuCl₄ ⋅ xH₂O), sodium hydroxide (NaOH), trisodium citrate (Na₃C₆H₅O₇), O-(2-(3-mercaptopropionylamino)ethyl)-O’-methylypolyethylene glycol [thiol-terminated poly(ethylene glycol)], referred to as PEG (molecular weight 5000), glutathione (C₅H₇N₂O₆S), and dithiothreitol (DTT, C₅H₇O₂S₂) were purchased from Sigma Aldrich (Dorset, UK). Chloroaucic acid, trisodium citrate, and sodium hydroxide stock solutions were prepared using distilled water (15 MΩ cm) at concentrations of 0.2 wt%, 1%, and 0.1 M, respectively. Freshly prepared solutions of glutathione (5 mM and 10 mM) and DTT (7 mg/mL) were made in distilled water before the release experiments. Bodipy FL-L-cystine (C₅H₇N₂O₆S), purchased from Invitrogen (Paisley, UK) and stored at −20°C. The 0.5 mg/mL solution used to functionalize gold nanoparticles was prepared in distilled water using DTT and stored at −4°C.

Synthesis of gold nanoparticles

Gold nanoparticles were prepared using a modified Turkevich and Frens method as previously described. Briefly, 4.5 mL of 1 wt% sodium citrate solution was added to 200 mL of boiling 0.01 wt% chloroaucic acid solution, refluxed for one hour, and then allowed to cool to room temperature with continuous stirring, yielding colloidal gold with a concentration of 0.058 mg/mL or 0.29 mM. NaOH solution (0.1 M, 500 μL) was added to 20 mL batches of gold nanoparticle colloid under stirring in order to adjust the pH to 8.0. Nanoparticles at pH 8.0 were used for all subsequent experimentation, including surface modification by Bodipy and Bodipy-PEG.

Bodipy-PEG conjugate formation

Bodipy FL L-cystine 1 mg comes in a lyophilized dimer form, and 2 mL of DTT 7 mg/mL was added to that to make a 0.5 mg/mL solution of Bodipy. This solution was then vortexed in an Eppendorf tube for about 20 minutes at room temperature to form Bodipy monomer, as shown in Figure 1. The Bodipy-DTT solution was dialyzed three times with water changes to remove the DTT from the Bodipy solution. The dialyzed thiol-terminated Bodipy solution was taken in precalculated...
concentrations (0.5, 1.0, 1.5, and 2.0 μg per mL of colloidal gold) and added to the gold nanoparticles (in 20 mL batch sizes). Next, 0.5, 1.0, and 1.5 μg/mL of Bodipy were added with various amounts of PEG (6.25, 12.50, and 18.75 μg/mL) to the gold nanoparticles in 20 mL batches and stirred overnight to prepare cofunctionalized nanoparticles with 0.5–18.75, 1.0–12.50, and 1.5–6.25 μg/mL of Bodipy-PEG, as shown in Figure 2. The Bodipy and Bodipy-PEG functionalized gold nanoparticles were then further dialyzed to remove any residual reactants, and stored at 4°C.

Characterization of gold nanoparticles alone and those conjugated with Bodipy and Bodipy-PEG

The gold nanoparticles were characterized using ultraviolet-visible spectroscopy, dynamic light scattering, zeta potential measurement, and Fourier transform infrared spectroscopy. A PerkinElmer Lambda 35 ultraviolet-visible spectrometer was used for collecting the absorbance spectra of all samples from 400 nm to 700 nm at 0.1 nm intervals. For size and zeta potential measurements, a Malvern Zetasizer Nano-ZS series from 400 nm to 700 nm at 0.1 nm intervals. For size and zeta potential measurements, a Malvern Zetasizer Nano-ZS series was used for collecting the absorbance spectra of all samples prepared into pellets with KBr using a Varian 640-IR Fourier transform infrared spectrometer in diffuse reflectance mode at 4 cm⁻¹ resolution between 400 cm⁻¹ and 4000 cm⁻¹. Transmission electron microscopy was used to characterize the size and shape of the gold nanoparticles. Transmission electron microscopy images were collected using a Philips TECNAI system (Eindhoven, The Netherlands) at 200 kV and the samples were dried at room temperature onto carbon-coated copper grids.

Stability of gold nanoparticles conjugated with Bodipy and Bodipy-PEG in glutathione

The stability of “as-synthesized” gold nanoparticles and gold nanoparticles capped with 0.5 and 2.0 μg/mL of Bodipy and with 0.50–18.75, 1.0–12.5, and 1.50–6.25 μg/mL of Bodipy-PEG were examined using ultraviolet-visible spectroscopy in both 5 mM and 10 mM glutathione solutions.

Glutathione-mediated Bodipy release

To investigate Bodipy release from gold nanoparticles functionalized with Bodipy and Bodipy-PEG, 0, 5, and 10 mM glutathione solutions were made up using 1 mL of functionalized colloidal gold. Next, 1 mL of toluene was added over the gold suspension, and Bodipy release into the toluene layer was studied by photoluminescence for 5 days. Use of the toluene layer was necessary because the hydrophobic Bodipy tends to aggregate in water. Photoluminescence was recorded using an inhouse system. The software used was Solis 4.19.30 with acquisition mode DDG on, accumulation number 20, slit 500 μm, gain 50, transistor-transistor logic width 400, and a system temperature of −10°C. Bodipy release over a period of 5 days in 5 mM and 10 mM glutathione was characterized by photoluminescence counts at 513 nm as a result of excitation at 340 nm. The release experiment was maintained at 37°C.

Figure 1. FL L-cystine dissociation to form monomer in presence of dithiothreitol.

Figure 2. Schematic representation for synthesis of gold nanoparticles conjugated with BODIPY® and with BODIPY-PEG.

Abbreviations: PEG, poly(ethylene glycol); AuNPs, gold nanoparticles.
using a water bath (schematic representation, Supplementary Figure 11).

Results and Discussion

Ultraviolet-visible spectroscopy

Figure 3A and B shows ultraviolet-visible and photoluminescence spectra for the free Bodipy molecule in water, which has not previously been reported in the literature. The ultraviolet-visible spectra for the three concentrations measured show two characteristic absorbance peaks at 479.3 nm and 503.5 nm. Photoluminescence (PL) measurements of the aqueous solutions excited at 340 nm displayed a characteristic emission peak at 513 nm.

Figure 4 shows the ultraviolet-visible absorbance spectra of gold nanoparticles conjugated with Bodipy and with Bodipy-PEG. The Lambda Max and absorbance for each sample is given in Table 1. With increasing amounts of Bodipy functionalization from 0.0 µg/mL to 2.0 µg/mL, the position of Lambda Max increased from 518.1 nm to 520.7 nm, which is indicative of an increase in diameter resulting from attachment of Bodipy. In the case of the Bodipy-PEG cofunctionalized gold nanoparticles, the position of Lambda Max increased from 518.1 nm for as-synthesized gold nanoparticles to 520.6–521.5 nm for gold nanoparticles conjugated with Bodipy-PEG. Peaks for free Bodipy were not observed in the spectra of the functionalized gold nanoparticles due to the quenching properties of the gold nanoparticles. The ultraviolet-visible spectra of the functionalized gold nanoparticles prepared with more than 2.0 µg/mL of Bodipy displayed peaks at 479.3 nm and at 503.5 nm as a result of free Bodipy in the solution. These peaks were not visible after washing by dialysis.

Dynamic light scattering and zeta potential measurement

The dynamic light scattering results shown in Figure 5 show a slight increase in hydrodynamic radius from 19.3 for the as-synthesized nanoparticles to 19.6 nm with pH adjustment to 8.0, and to 20.4–21.9 nm with increasing amounts of Bodipy functionalization up to 2 µg/mL. Photoluminescence measurements of the supernatant remaining after the gold nanoparticles have been removed using centrifugation showed that the gold nanoparticle surface begins to saturate with Bodipy at an addition rate of 1.5 µg/mL. At higher addition levels, it was found that excess Bodipy remained in the supernatant (see Supplementary Figure 10). A diameter of about 40.6 nm was measured for gold nanoparticles functionalized only with 25.0 µg/mL of PEG. This level of PEG has been previously shown to equate to almost complete surface saturation, with the PEG monolayer adopting an extended random coil conformation. A relatively small reduction in diameter compared with the fully PEG-capped gold nanoparticles of 38–39 nm was measured for the 0.5–18.75 and 1.0–12.5 µg/mL gold nanoparticles cofunctionalized with Bodipy-PEG. This demonstrates that reducing the density of PEG functionalization by some 50% and attaching Bodipy to the gold nanoparticle surface does not dramatically alter the PEG conformation. Gold nanoparticles functionalized with 6.25 µg/mL of PEG, which is equivalent to approximately 25% surface coverage and 1.25 µg/mL of Bodipy, displayed a diameter of about 32 nm. This low packing density results in the PEG adopting a somewhat less extended conformation producing a smaller hydrodynamic radius. Dynamic light scattering measurements recorded a surface charge (zeta potential) of ~45 mV for the pH-adjusted citrate-capped gold nanoparticles.
gold nanoparticles, rising to $-34$ mV with increasing amounts of Bodipy capping. This compared with $-7$ mV for the 25.0 µg/mL PEG-capped nanoparticles. Gold nanoparticles cofunctionalized with both Bodipy and PEG display intermediate levels of surface charge in the range of $-25$ mV to $-19$ mV with increasing amounts of PEG.

Transmission Electron Microscopy

Transmission electron microscopic images for as-prepared gold nanoparticles and those functionalized with Bodipy and/or PEG are shown in Figure 6. The somewhat faceted spherical particles show a largely monodispersed size distribution with an average (± standard deviation) size of 15.5 ± 1.53 nm for the as-synthesized gold nanoparticles. As expected, the size of the functionalized gold nanoparticles measured using transmission electron microscopy was not significantly different to the as-synthesized gold nanoparticles because transmission electron microscopy is not sensitive to the organic coating at the acceleration voltage used. For each sample type, some 80–120 nanoparticles were counted in order to calculate size and standard deviation using Image J software and the statistics option in Origin 7.0.

Fourier transform infrared spectroscopy

The presence of PEG on the surface of the gold nanoparticle conjugated with PEG is confirmed by the bands at 3000–2850 cm$^{-1}$ (–CH$_2$ stretching), 1631 cm$^{-1}$ (N–H bending), 1660 cm$^{-1}$ (C=O stretching), 1380 cm$^{-1}$ (C–H bending; –CH$_3$ and –CH$_2$), 1100 cm$^{-1}$ (C–O–C stretching), and 600–900 cm$^{-1}$ (N–H wagging)$^{35,37}$ (see Supplementary Figure 1). In the case of gold nanoparticles conjugated with Bodipy-PEG, peaks at 3190 cm$^{-1}$ [ν(N–H, O–H)], 2969–2850 cm$^{-1}$ [ν(C–H)], about 1710, 1604–1400 cm$^{-1}$ [vas (C=O), vs (COO–)], 1350–1250 cm$^{-1}$ [ν(C–N)], about 1625 (C=C), 3100–3010 (C–H, ring), 3550–2500 (carboxylic O–H, broad) and in the 2969–2850 cm$^{-1}$ region ν(C–H), as shown in Figure 7, confirm the presence of both Bodipy and PEG on the gold nanoparticle surface. The bonding of both groups to the gold nanoparticle surface in a mixed monolayer is further demonstrated by the peaks missing at 2550 cm$^{-1}$ and 945 cm$^{-1}$ (–SH) in the spectra for gold nanoparticles conjugated with Bodipy-PEG, which are present in the spectra of pure Bodipy and PEG.$^{38}$ The absence of these peaks is attributed to the breakup of the –SH group, which results from the bonding of thiolated Bodipy and PEG with the gold nanoparticle surface. Fourier transform infrared spectra for gold nanoparticles capped solely with PEG (25 µg/mL) and Bodipy (1.0 and 2.0 µg/mL) are given in Supplementary Figures 1 and 2.

Stability of gold nanoparticles conjugated with Bodipy and Bodipy-PEG

It is widely reported in the literature that as-synthesized citrate-capped gold nanoparticle colloids are stable for

---

**Table 1** Ultraviolet-visible characteristics of AuNPs samples modified with BODIPY and or PEG with corresponding Lambda Max and absorbance values

<table>
<thead>
<tr>
<th>Sample name</th>
<th>BODIPY µg/mL</th>
<th>PEG-SH µg/mL</th>
<th>Lambda Max (nm)</th>
<th>Absorbance</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.0</td>
<td>2.0</td>
<td>–</td>
<td>520.68</td>
<td>0.80</td>
</tr>
<tr>
<td>1.5–6.25</td>
<td>1.5</td>
<td>6.25</td>
<td>521.50</td>
<td>0.75</td>
</tr>
<tr>
<td>1.0–12.50</td>
<td>1.0</td>
<td>12.50</td>
<td>521.10</td>
<td>0.79</td>
</tr>
<tr>
<td>0.5–18.75</td>
<td>0.5</td>
<td>18.75</td>
<td>520.60</td>
<td>0.81</td>
</tr>
<tr>
<td>25.00</td>
<td>–</td>
<td>25.00</td>
<td>520.75</td>
<td>0.80</td>
</tr>
<tr>
<td>1.5</td>
<td>1.5</td>
<td>–</td>
<td>519.83</td>
<td>0.81</td>
</tr>
<tr>
<td>1.0</td>
<td>1.0</td>
<td>–</td>
<td>519.11</td>
<td>0.79</td>
</tr>
<tr>
<td>0.5</td>
<td>0.5</td>
<td>–</td>
<td>518.81</td>
<td>0.81</td>
</tr>
<tr>
<td>AuNPs-AP</td>
<td>–</td>
<td>–</td>
<td>518.7</td>
<td>0.87</td>
</tr>
<tr>
<td>AuNPs-8pH</td>
<td>–</td>
<td>–</td>
<td>518.11</td>
<td>0.82</td>
</tr>
</tbody>
</table>

**Abbreviations:** AuNPs, gold nanoparticles; AP, As Prepared; PEG-SH, thiolated Poly ethylene glycol.
extended periods at room temperature. However, the addition of PEG-capping also renders the gold nanoparticles stable in a wide range of media, including organic solvents, and at physiological salt concentrations. The stability of 0.5 µg/mL Bodipy-capped and 0.5–18.75 µg/mL Bodipy-PEG-capped gold nanoparticles were evaluated in 5 mM and 10 mM glutathione. The black trace in Figure 8A and B denotes the ultraviolet-visible spectra prior to addition of glutathione. The large upshift in peak position observed in the gold nanoparticles conjugated with Bodipy as a result of addition.

![Figure 5](image.png)

**Figure 5** Dynamic light scattering and zeta potential of gold nanoparticles coated with (A) BODIPY® and (B) BODIPY-PEG.

**Abbreviations:** DLS, dynamic light scattering; PEG, poly(ethylene glycol); AuNPs, gold nanoparticles.

![Figure 6](image.png)

**Figure 6** Transmission electron microscopic images for gold nanoparticles (A). Gold nanoparticles conjugated with BODIPY® (2.0 µg/mL), (B). Gold nanoparticles conjugated with BODIPY-PEG (1.5–6.25 µg/mL), (C). And gold nanoparticles conjugated with PEG (25.0 µg/mL) (D).

**Note:** Scale is 20 nm at 145,000×.

**Abbreviation:** PEG, poly(ethylene glycol).
of glutathione is indicative of significant aggregation. This is confirmed by the insert image in Figure 8A, with a blue color observed with in minutes after the addition of glutathione, while the insert images of Bodipy-PEG-conjugated gold nanoparticle solutions in Figure 8B still show the characteristic red color of colloidal gold after addition of glutathione. The Bodipy-PEG-conjugated gold nanoparticles show excellent stability, with no upshift in ultraviolet-visible peak position and only a slight decrease in absorbance over time. The stability graphs of ultraviolet-visible absorbance spectra for as-synthesized gold nanoparticles and those functionalized with Bodipy and/or PEG formulations in 5 mM and 10 mM of glutathione are shown in Supplementary Figures 3–9, and confirm the effect of PEG on stability.

Glutathione-mediated Bodipy release

Figure 9 shows the release of Bodipy from gold nanoparticles conjugated with Bodipy (1.0 µg/mL) and gold nanoparticles conjugated with Bodipy-PEG (1.0–12.5 µg/mL) in the presence of 5 mM and 10 mM glutathione. Glutathione contains a thiol group and acts as a reducing agent in cells to prevent damage caused by reactive oxygen species, such as free radicals. The photoluminescence of the released Bodipy displayed peaks equivalent to those of free Bodipy, demonstrating that attachment and release of the dye from the gold nanoparticle surface has not altered its fluorescent behavior. Comparing the release profile from gold nanoparticles functionalized with 1.0 µg/mL of Bodipy with and without 12.5 µg/mL of PEG cofunctionalization, it is apparent that the presence of PEG has a significant influence on Bodipy release. Gold nanoparticles conjugated with Bodipy show an initial burst release in the presence of 5 mM and 10 mM glutathione, whereas gold nanoparticles conjugated with Bodipy-PEG show controlled release. Without PEG functionalization, the gold nanoparticles display an initial burst release followed by a prolonged period of sustained release over a period of 120 hours. It is postulated that the initial burst release occurs during aggregation of the gold nanoparticles, and that this aggregation slows the subsequent release. However, with the addition of PEG capping no initial burst release is observed, with gradual release over an approximately 2-hour period. While the release profile differs, the total amount of Bodipy released over a 120-hour period in the presence of 10 mM glutathione is similar for the gold nanoparticles with and without addition of PEG. The slight reduction in the total amount of Bodipy released from the PEG cofunctionalized

Figure 7 Fourier transform infrared spectra for samples of gold nanoparticles conjugated with BODIPY®-PEG with left and right inset spectra of pure PEG and BODIPY, respectively. 
Abbreviation: PEG, poly(ethylene glycol).
gold nanoparticles may be a result of steric shielding. This effect is more evident at a glutathione concentration of 5 mM, with the total amount of Bodipy released over 120 hours significantly reduced by PEG cofunctionalization.

Figure 10A and B shows release of Bodipy expressed as a percentage of the initial amount attached from 0.5–18.75 μg/mL, 1.0–12.5 μg/mL, and 1.5–6.25 μg/mL gold nanoparticles cofunctionalized with Bodipy-PEG in 5 mM and 10 mM glutathione. Figure 10 also includes the Bodipy release profile from gold nanoparticles functionalized with 2.0 μg/mL of Bodipy in the absence of glutathione as a control. The limited release of Bodipy from gold nanoparticles conjugated with Bodipy in the absence of glutathione confirms the critical role that the tripeptide plays in mediating the release of thiol-bound payloads at typical intracellular levels.

In Figure 10, the release is expressed in wt% of the original amount of attached Bodipy calculated using a photoluminescence calibration curve of free Bodipy. As with the Bodipy release expressed as counts shown in Figure 9, no initial burst phase is observed for the cofunctionalized gold nanoparticles. Over the first 2 hours, 27.9, 22.8, and 19.2 wt% of the attached Bodipy is released from the nanoparticles in 5 mM glutathione for the 0.5–18.75, 1.0–12.5, and 1.5–6.25 μg/mL samples. This compares with 67.2, 46.1 and 39.2 wt% over the same period for 10 mM glutathione. Figure 10B shows the release profiles over a 5-day period, with up to 83.3% of the attached Bodipy released in the case of 0.5–18.75 μg/mL BODIPY-PEG functionalized gold nanoparticles. Experiments conducted with free Bodipy (see Supplementary Figure 13), by adding a layer of toluene to solutions containing 1.0 μg/mL of Bodipy in the presence of 0, 5, and 10 mM glutathione were also undertaken, and it was observed that glutathione not only helps in dissociation of Bodipy from the gold nanoparticle surface but also assists
in phase transfer of the Bodipy to the toluene layer. As compared with release in 0 mM glutathione (control), 2.3, 3.8, and 4.7 times higher Bodipy release was observed after 2 hours in 5 mM glutathione for 0.5–18.75, 1.0–12.50, and 1.5–6.25 µg/mL samples of gold nanoparticles functionalized with Bodipy-PEG, respectively.

**Conclusion**

The study has demonstrated cofunctionalization of gold nanoparticles with thiolated PEG and Bodipy, with the presence of both molecules confirmed via Fourier transform infrared spectroscopy. It was observed that the addition of Bodipy caused an increase in gold nanoparticle diameter, measured by dynamic light scattering, from 19.6 to 20–22 nm, compared with 32–39 nm for Bodipy and PEG cofunctionalization. For gold nanoparticles cofunctionalized with Bodipy-PEG, addition of PEG rendered the gold nanoparticles stability at intracellular glutathione levels, while the gold nanoparticle samples conjugated only with Bodipy displayed significant aggregation. The glutathione-mediated release studies showed that the addition of PEG to gold nanoparticles stops the initial burst release of Bodipy observed in samples without PEG. However, addition of PEG reduced the total amount of Bodipy released, especially at a glutathione concentration of 5 mM. It was observed that up to about 83% of the attached Bodipy was released from the cofunctionalized gold nanoparticles in the presence of 10 mM glutathione. The study confirms the role of PEG in stabilizing gold nanoparticles and describes the payload release behavior of gold nanoparticles capped with a mixed monolayer. Varying the amount of PEG functionalization and glutathione concentration enables control of the loading capacity and release profile of Bodipy.

**Acknowledgments**

We acknowledge Somak Mitra and Davide Mariotti for the photoluminescence spectroscopy and Isha Mutreja and Susmita Mitra for their support and guidance. Department for Employment and Learning and Cross Border Research Funding are also thanked for funding this project.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


Supplementary figures

Figure S1 Fourier transform infrared absorbance spectra for 25 µg/mL PEG capped gold nanoparticles.
Abbreviations: AuNPs, gold nanoparticles; PEG, poly(ethylene glycol).

Figure S2 Fourier transform infrared absorbance spectra for 1.0 µg/mL and 2.0 µg/mL of BODIPY® on the surface of gold nanoparticles.
Figure S3 Ultraviolet-visible absorbance spectra for gold nanoparticles conjugated with PEG (25.0 µg/mL), stability in 10 mM glutathione (GSH).

Abbreviations: PEG, poly(ethylene glycol); AP, as prepared sample and in GSH after 60 minutes.

Figure S4 Ultraviolet-visible absorbance spectra for gold nanoparticles capped with BODIPY® (2.0 µg/mL), and their stability in 5 mM glutathione (GSH) (samples show as prepared [AP] and GSH in 60 minutes).
**Figure S5** Ultraviolet-visible absorbance spectra for stability of as-prepared gold nanoparticles in 5 mM and 10 mM glutathione solution (samples show as prepared [AP] and in GSH after 60 minutes).

**Abbreviations:** AuNPs, gold nanoparticles; PEG, poly(ethylene glycol).

**Figure S6** Ultraviolet-visible absorbance spectra for stability of gold nanoparticles conjugated with 0.5 and 2.0 µg/ml of BODIPY® in 10 mM glutathione. (samples show as prepared [AP] and in GSH after 60 minutes).

**Abbreviation:** GSH, glutathione.

**Figure S7** Ultraviolet-visible absorbance spectra for stability of gold nanoparticles conjugated with 1.0-12.5 µg/ml of BODIPY®-PEG in 5 and 10 mM glutathione. (AP-As Prepared Sample and in GSH after 60 minute and on day 5).

**Abbreviation:** GSH, glutathione.
Figure S8 Ultraviolet-visible absorbance spectra for stability of gold nanoparticles conjugated with 1.5–6.25 µg/ml of BODIPY®-PEG in 5 mM and 10 mM glutathione (GSH). As prepared (AP) sample and in GSH after 60 minutes and on day 5.

Abbreviations: PEG, poly(ethylene glycol).

Figure S9 Ultraviolet-visible absorbance spectra for stability of gold nanoparticles conjugated with BODIPY®-PEG (0.5–18.75 µg/mL), and stability in 10 mM glutathione (GSH). As prepared (AP) sample and in GSH after 60 minutes and on day 5.

Abbreviations: PEG, poly(ethylene glycol).
**Figure S10** Amount of free BODIPY® present in supernatant after AuNP-BODIPY nanoparticles centrifugation with increasing concentration of BODIPY.

**Figure S11** Schematic representation for release of BODIPY® and transfer to the toluene.
Figure S12. PL count data for AuNPs conjugated with various concentrations of BODIPY-PEG. Abbreviation: PEG, poly(ethylene glycol).

Figure S13. PL count graph for pure BODIPY solution in GSH (0, 5 and 10 mM) and 2.0 µg/mL AuNP-BODIPY (0 mM-GSH) as a control.